Anzeige
Meldung des Tages: Warum diese Aktie einer der großen Gewinner im neuen Goldzyklus sein könnte

Blueprint Medicines Corp News

Aktie
WKN:  A14SDD ISIN:  US09627Y1091 US-Symbol:  BPMC Branche:  Biotechnologie Land:  USA
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
-
KGV
-82,28
Index-Zuordnung
-

Blueprint Medicines Corp News

18.07.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: VRNA, BPMC, DALN, and RGLD PR Newswire
23.06.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SAGE, SOL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SAGE, SOL on Behalf of Shareholders PR Newswire
12.06.25 - PR Newswire
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-​Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 ...
03.06.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders PR Newswire
02.06.25 - wallstreetONLINE Redaktion
Milliarden-Übernahme: Sanofi kauft sich mit 9,1 Milliarden US-Dollar in US-Biotech-Markt ein!
Der französische Pharmariese Sanofi kündigt milliardenschweren Übernahme von Blueprint Medicines an. Die Ankündigung lässt die Aktie in die Höhe steigen!Der französische ...
02.06.25 - PR Newswire
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-​stage pipeline in immunology PR Newswire
01.05.25 - PR Newswire
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance PR Newswire
25.04.25 - PR Newswire
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 PR Newswire
31.03.25 - PR Newswire
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference PR Newswire
28.02.25 - PR Newswire
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-​Targeted Therapies at 2025 AAAAI / WAO Joint Congress PR Newswire
13.02.25 - PR Newswire
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results PR Newswire
08.02.25 - Börse-Global
Blueprint Medicines Aktie: Neue Sorgen am Horizont?
Die Blueprint Medicines Corporation verzeichnete am 8. Februar 2025 einen signifikanten Kursrückgang von 4,23 Prozent auf 104,98 USD. Diese Entwicklung erfolgt wenige Tage ...
05.02.25 - PR Newswire
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »